Tests elecoglipron against placebo in adults with chronic kidney disease
Tests elecoglipron versus placebo in adults with chronic kidney disease, alongside standard care.
Plain-language title generated from the registry record
Registry title: A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
Key facts
- Where
- Aachen, Ahrensburg, Bad Mergentheim, Bad Nenndorf, Bamberg, Berlin, Brandenburg An Der Havel, Brunswick, Chemnitz, Cloppenburg, Dortmund, Dresden, Duesseldorf, Duisburg, Erlangen, Essen, Frankfurt am Main, Freiburg, Fulda, Gladbeck, Goettingen, Goslar, Hamburg, Hanover, Heidelberg, Herne, Kiel, Landshut, Leipzig, Luebeck, Magdeburg, Mannheim, München, Munich, Nuremberg, Reinfeld, Riesa, Rostock, Rotenburg, Stuttgart, Trier, Ulm, Wiesbaden, and Wuerzburg, GermanySee the 57 sites
- Phase
- Phase 3
Where in Germany
- Universitaetsklinikum Aachen AöRAachen, GermanyTaking people
- Velocity Clinical Research Germany GmbHAhrensburg, GermanyTaking people
- MVZ DiaMedicum Bad Mergentheim GmbHBad Mergentheim, GermanyTaking people
- Nephrologische Praxis Bad NenndorfBad Nenndorf, GermanyTaking people
- Sozialstiftung BambergBamberg, GermanyTaking people
- Charite Universitaetsmedizin Berlin KöRBerlin, GermanyTaking people
- Epimed Gesellschaft fuer epidemiologische und klinische Forschung in der Medizin mbHBerlin, GermanyTaking people
- Studienzentrum Dr. Braun GmbHBerlin, GermanyTaking people
- Velocity Clinical Research Germany GmbHBerlin, GermanyTaking people
- Vivantes Netzwerk fuer Gesundheit GmbHBerlin, GermanyTaking people
- Universitaetsklinikum Brandenburg an der Havel GmbHBrandenburg An Der Havel, GermanyTaking people
- Staedtisches Klinikum Braunschweig gGmbHBrunswick, GermanyTaking people
- Klinikum Chemnitz gGmbHChemnitz, GermanyTaking people
- St. Josefs-Hospital Cloppenburg gGmbHCloppenburg, GermanyTaking people
- Klinikum Dortmund gGmbHDortmund, GermanyTaking people
- Universitaetsklinikum Carl Gustav Carus Dresden an der Technischen Universitaet Dresden AöRDresden, GermanyTaking people
- Universitaetsklinikum Duesseldorf AöRDuesseldorf, GermanyTaking people
- StudyPoint Duisburg GbRDuisburg, GermanyTaking people
- Universitaetsklinikum Erlangen AöRErlangen, GermanyTaking people
- Universitaetsklinikum Essen (AoR)Essen, GermanyTaking people
- Agaplesion Frankfurter Diakonie Kliniken gGmbHFrankfurt am Main, GermanyTaking people
- ClinPhenomics CVC GmbHFrankfurt am Main, GermanyTaking people
- Nierenzentrum FreiburgFreiburg, GermanyTaking people
- MVZ im Altstadt-Carree Fulda GmbHFulda, GermanyTaking people
- Hausarztzentrum ButendorfGladbeck, GermanyTaking people
- Universitaetsmedizin GoettingenGoettingen, GermanyTaking people
- Asklepios Harzkliniken GmbHGoslar, GermanyTaking people
- Diabetes Zentrum Wilhelmsburg GbRHamburg, GermanyTaking people
- Velocity Clinical Research Germany GmbHHamburg, GermanyTaking people
- Medizinische Hochschule HannoverHanover, GermanyTaking people
- Zentrum Fuer Nieren Hochdruck Und StoffwechselerkrankungenHanover, GermanyTaking people
- Universitaetsklinikum Heidelberg AöRHeidelberg, GermanyTaking people
- St. Elisabeth Gruppe GmbH Katholische Kliniken Rhein-RuhrHerne, GermanyTaking people
- Universitaetsklinikum Schleswig-Holstein AöRKiel, GermanyTaking people
- Internistische Gemeinschaftspraxis und Dialysezentrum LandshutLandshut, GermanyTaking people
- LA-Regio Kliniken gKU AöR des Landkreises und der Stadt LandshutLandshut, GermanyTaking people
- Familienmedizinisches Zentrum RadowskyLeipzig, GermanyTaking people
- Klinikum St. Georg gGmbHLeipzig, GermanyTaking people
- Velocity Clinical Research Germany GmbHLeipzig, GermanyTaking people
- Velocity Clinical Research Germany GmbHLuebeck, GermanyTaking people
- SMO.MD GmbHMagdeburg, GermanyTaking people
- Universitaetsklinikum Magdeburg AöRMagdeburg, GermanyTaking people
- Universitaetsklinikum Mannheim GmbHMannheim, GermanyTaking people
- Studienpraxis HeimeranplatzMünchen, GermanyTaking people
- LMU Klinikum Muenchen AöRMunich, GermanyTaking people
- Klinikum NuernbergNuremberg, GermanyTaking people
- MVZ Medic Center NuernbergNuremberg, GermanyTaking people
- Praxis Reinfeld MitteReinfeld, GermanyTaking people
- Elblandkliniken Stiftung & Co.KGRiesa, GermanyTaking people
- Zentrum Fuer Innere MedizinRostock, GermanyTaking people
- Facharztpraxis für NierenheilkundeRotenburg, GermanyTaking people
- Robert Bosch Gesellschaft fuer medizinische Forschung mbHStuttgart, GermanyTaking people
- Diabetologische Schwerpunktpraxis Dr. Schmidt-ReinwaldTrier, GermanyTaking people
- Endokrinologikum UlmUlm, GermanyTaking people
- Universitaetsklinikum Ulm AoRUlm, GermanyTaking people
- Velocity Clinical Research Germany GmbHWiesbaden, GermanyTaking people
- Universitaetsklinikum Wuerzburg AöRWuerzburg, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07753993EU 2025-523994-41-00
- Record updated
- 9 September 2026
- Original description
This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled multicenter study to investigate outcomes with elecoglipron compared with placebo in participants with CKD with and without T2DM who are on background SGLT2i (dapagliflozin) as GDMT and other SoC treatments for CKD.Read full original descriptionShow less
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants With Chronic Kidney Disease (Elevate-CKD)
This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled multicenter study to investigate outcomes with elecoglipron compared with placebo in participants with CKD with and without T2DM who are on background SGLT2i (dapagliflozin) as GDMT and other SoC treatments for CKD.
Inclusion: Adults with confirmed CKD; UACR ≥30 mg/g and eGFR ≥20 mL/min/1.73 m² within specified ranges; On stable, patient maximum tolerated, labeled daily dose of ACEI or ARB for ≥4 weeks at least 28 days before screening.
Exclusion: Currently receiving, or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema; Have had more than one episode of severe hypoglycemia within 180 days prior to screening, or hypoglycemia unawareness; Acute coronary syndrome, major cardiac procedure, stroke, or TIA within 3 months prior to screening; History of type 1 diabetes mellitus; Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying; History of acute or chronic pancreatitis; History/family history (first degree) of medullary thyroid cancer or MEN2; HbA1c ≥10% (86 mmol/mol) at screening; BMI <23 kg/m² at screening.